Breaking News
January 23, 2019 - Scientists reveal new mechanism that could lead to specific treatment of strokes and seizures
January 23, 2019 - Both educational level and occupational orientation predict mother’s smoking during pregnancy
January 23, 2019 - How to (gently) get your child to brush their teeth
January 23, 2019 - Short-term hospital readmissions for gun injuries cost $86 million a year | News Center
January 23, 2019 - New certified reference material for testing residual solvents in cannabis
January 23, 2019 - Gene-edited chickens could prevent future flu pandemic
January 23, 2019 - Cardiovascular disease risk begins even before birth
January 23, 2019 - Younger patients receiving kidney transplant more likely to live longer, shows data
January 23, 2019 - Skin samples hold early signs of prion disease, research suggests
January 23, 2019 - Researchers discover how body initiates repair mechanisms that limits damage to myelin sheath
January 23, 2019 - Fecal transplant from certain donors better than others
January 23, 2019 - Risk for Uninsurance in AMI Patients Reduced With Medicaid Expansion
January 23, 2019 - Readmissions reduction program may be associated with increase in patient-level mortality
January 23, 2019 - Fostering translation and communication in medicine and beyond
January 23, 2019 - To Fight Fatty Liver, Avoid Sugary Foods and Drinks
January 23, 2019 - TPU scientists develop new implants that double the rate of bone lengthening in kids
January 23, 2019 - New sessions at Pittcon 2019
January 23, 2019 - Insilico to present latest findings in AI for Drug Discovery at 3rd Annual SABPA FTD Forum
January 23, 2019 - Opioid overdose patients can be safely discharged an hour after administration of naloxone
January 23, 2019 - Scientists find bacterial extracellular vesicles in human blood
January 23, 2019 - Researchers gain new insights into development of necrotizing enterocolitis in preemies
January 23, 2019 - Medical expert advises people with epilepsy not to stockpile medicines
January 23, 2019 - Study outlines research priorities for improving pediatric patient care and safety
January 23, 2019 - Bedfont to exhibit NObreath FeNO monitor at Arab Health 2019
January 23, 2019 - Nicotinamide riboside supplementation confers significant physiological benefits to mothers and offspring
January 23, 2019 - Increasing temperatures may help preserve crop nutrition
January 23, 2019 - Many Oncologists in the Dark About LGBTQ Health Needs
January 23, 2019 - Epigenetic change causes fruit fly babies to inherit diet-induced heart disease
January 23, 2019 - Erasing memories could reduce relapse rates among drug addicts
January 23, 2019 - African Americans who smoke cigarettes are more likely to develop peripheral artery disease
January 23, 2019 - Unique data combination helps FinnGen researchers to fund links between genetic factors and health
January 23, 2019 - Parents’ mental health problems associated with reactive attachment disorder in children
January 23, 2019 - Graphene Flagship project studies impact of graphene and related materials on our health
January 23, 2019 - The connection between the Pope and contraceptive pills
January 23, 2019 - Prior dengue infection could protect children from symptomatic Zika
January 23, 2019 - Previous dengue virus infection associated with protection from symptomatic Zika
January 23, 2019 - VISTA checkpoint implicated in pancreatic cancer immunotherapy resistance
January 23, 2019 - The Tiny Camera That Could Revolutionize Cardiovascular Surgery
January 23, 2019 - Peptide isolated from soil fungi has antitumor and antibacterial properties
January 23, 2019 - TGen identifies polio-like virus as potential cause of Acute Flaccid Myelitis outbreak
January 23, 2019 - Migrants and refugees do not bring disease and are at greater health risk themselves says WHO
January 23, 2019 - Examing the effects of menopause in workplace
January 23, 2019 - Enemy number 1 – Air pollution and climate change top of WHO agenda
January 23, 2019 - Two Positive Phase III studies of Tafenoquine for the Radical Cure of Plasmodium vivax Malaria Published in The New England Journal of Medicine
January 23, 2019 - World Trade Center responders at increased risk for head and neck cancers
January 23, 2019 - Low-sugar diet leads to significant improvement in nonalcoholic fatty liver disease in boys
January 23, 2019 - Chaos in bodily regulation can optimize our immune system, finds study
January 23, 2019 - Short, text-based exercises can increase happiness for adults recovering from substance use disorders
January 23, 2019 - Body size may have greater influence on women’s lifespan than men
January 23, 2019 - Groundbreaking tool helps visualize neuronal activity with near-infrared light
January 23, 2019 - Prior dengue immunity in children may be protective against symptomatic Zika
January 23, 2019 - Holocaust survivors with PTSD and their offspring exhibit more unhealthy behavior patterns
January 23, 2019 - Scientists discover new genetic mutations causing inherited deaf-blindness
January 23, 2019 - UC team designs new naloxone-dispensing smart device
January 23, 2019 - Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide Tablets, USP
January 23, 2019 - Brain activity shows development of visual sensitivity in autism
January 23, 2019 - Two hour gap between dinner and sleep is overrated says Japanese research
January 23, 2019 - Fear and embarrassment are causing smear test numbers to plummet
January 23, 2019 - Protein-secreting device implanted in epileptic rats reduces seizures, improves cognition
January 23, 2019 - Reintroduction project recovers current wild population of green turtle in Cayman Islands
January 23, 2019 - Cancer survivors face greater financial burden related to medical bills
January 23, 2019 - PSA screening reduces prostate cancer deaths by 30%
January 23, 2019 - LSTM receives grant to help improve health of people living in informal settlements
January 23, 2019 - Hemochromatosis Mutation Linked to Other Morbidity
January 23, 2019 - Why early diagnosis of autism should lead to early intervention
January 23, 2019 - Aspirin May Lower Stroke Risk in Women with History of Preeclampsia
January 23, 2019 - Exposure to certain chemicals may be linked to decrease in blood pressure during pregnancy
January 23, 2019 - Bowel cancer on the rise among younger Australians
January 23, 2019 - Scientists have reversed memory loss in a mouse model of Alzheimer’s
January 23, 2019 - Defective molecular master switch could lead to age-related macular degeneration
January 23, 2019 - Researchers identify how concussions may contribute to seizures
January 23, 2019 - Short interval between last meal of the day and bedtime may not affect blood glucose levels
January 23, 2019 - Still Too Many Highway Deaths Tied to Speeding
January 23, 2019 - Prenatal valproate exposure linked to increased ADHD risk
January 23, 2019 - Compound identified that may help treat heart failure
January 23, 2019 - Undiagnosed Asthma in Urban Adolescents May Be Common
January 23, 2019 - Study describes metabolism of intestinal microbiota in babies for the first time
January 22, 2019 - Study links concussions to development of epilepsy
January 22, 2019 - Specialist-led hospital bereavement service may help restrain legal action after difficult deaths
January 22, 2019 - Genetic study reveals possible new routes to treating osteoarthritis
Bortezomib No Help for Kidney Transplant Rejection

Bortezomib No Help for Kidney Transplant Rejection

image_pdfDownload PDFimage_print

Action Points

  • Note that this small randomized trial found no evidence that the anti-plasma cell agent bortezomib is efficacious at reducing antibody-mediated rejection in kidney transplant.
  • Given the higher rate of adverse events in the bortezomib group, the future for the agent in this population does not look bright.

The proteasome inhibitor bortezomib (Velcade) failed to counteract late antibody-mediated rejection in kidney transplant patients, researchers reported from a small randomized trial.

In the placebo-controlled clinical study, overall graft survival at 2 years did not differ significantly between treatment arms and, in fact, numerically favored placebo (81% versus 96%; P=0.12). Patient survival also was no better with bortezomib than placebo (90% versus 100%, respectively; P=0.13), said Georg Böhmig, MD, of the Medical University of Vienna in Austria, and colleagues.

The trial’s primary endpoint, the change in estimated glomerular filtration rate (eGFR) over two years, was not significantly different between the treatment and placebo groups. The eGFR slope was -4.7 for the treatment group and -5.2 for placebo (difference 0.5; 95% CI -4.8 to 5.8; P=0.86), Böhmig and colleagues reported online in the Journal of the American Society of Nephrology.

The drug also had no apparent impact on donor-specific antibodies (DSA). Change in DSA at two years was not significantly different between the treatment and placebo groups, although substantial longitudinal variation of DSA in both groups made it difficult to detect a difference, the study authors reported.

Compounding the drug’s failure, overall adverse events were more common with bortezomib (91 versus 64) as were serious adverse events (10 versus 4). Bortezomib was associated with gastrointestinal toxicity, especially nausea and diarrhea. It was also associated with significantly higher grades of anemia, thrombocytopenia, and leukocytopenia, the study found.

“Our trial challenges the results of previous observational studies and argues against a beneficial effect of bortezomib as a treatment for late antibody-mediated rejection,” Böhmig and colleagues said. “The absence of an effect of bortezomib on DSA and disease activity is important because such effects would be expected, considering the known mechanism of action of the drug.”

Bortezomib, which is approved by the FDA for multiple myeloma and mantle cell lymphoma, promotes the apoptosis of plasma cells, they explained. However, “It is possible that the state of the plasma cells in late antibody-mediated rejection differs from that in other disease conditions in ways that render them less susceptible to the action of bortezomib,” they said.

The trial included 44 kidney transplant recipients diagnosed with late antibody-mediated rejection. They were randomized 1:1 to receive two cycles of either bortezomib or placebo at 3-month intervals in double-blinded fashion. Each treatment cycle consisted of bortezomib at 1.3 mg/m2, administered intravenously twice-weekly on days 1, 4, 8, and 11.

For antiviral prophylaxis, bortezomib-treated patients received oral valacyclovir at 500 mg/day for 3 weeks after initiation of each cycle. Patients in the control group received a 0.9% sodium chloride solution placebo, and instead of valacyclovir they received gelatin capsules filled with maltodextrin. Trial participants were followed for 24 months.

Despite the lack of efficacy reported in this trial, researchers should continue to explore the use of proteasome inhibitors to treat late antibody-mediated rejection of kidney transplants, Böhmig and colleagues said. “An interesting strategy to achieve a longer duration of inhibition and enhanced plasma cell depletion may be the use of new irreversible proteasome inhibitors, such as carfilzomib,” they said.

In addition, bortezomib may be more effective if combined with other agents or treatments, they suggested. “In this respect, the results of an ongoing trial designed to evaluate the effect of bortezomib as part of combinatorial treatment in late antibody-mediated rejection will be of interest,” they said. The Bortezomib in Rejection of Kidney Transplants (TRIBUTE) trial will assess the efficacy of bortezomib in combination with steroids, plasma exchange, and polyclonal intravenous immunoglobulins, according to clinicaltrials.gov.

Böhmig and colleagues noted some limitations to their trial, including using eGFR decline, the study’s main endpoint, as a surrogate of graft survival. However, “A study design to detect meaningful differences in survival rates would have necessitated a long-term multi-center trial including hundreds of patients. Even for our comparatively small trial, screening of more than 700 recipients was necessary for recruitment of less than 50 subjects eligible for the interventional part of the study,” they said.

The study was funded by the Austrian Science Fund and Sandoz GmbH, Austria.

No study authors reported relevant financial relationships.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

1969-12-31T19:00:00-0500

last updated

Tagged with:

About author

Related Articles